EFFECT OF COMBINED PHARMACOTHERAPY ON THE QUALITY OF LIFE IN PATIENTS WITH LOW BACK PAIN
DOI:
https://doi.org/10.61751/ijmmr/2.2023.23Keywords:
vital activity, treatment, theramine, tenoxicam, drug combinationsAbstract
Low back pain is a frequent symptom with which patients turn to doctors of various specialities. This is conditioned by its debilitating course and, not infrequently, to the lack of substantial improvement due to the conducted treatment, resulting in the significant reduction in the quality of life. The purpose of the study was to assess the effect of a medicinal food product and a nonsteroidal anti-inflammatory drug on the quality of life in patients with low back pain. The quality of life was assessed both in the control group (15) and in patients with low back pain (69) at the beginning of the therapy and on day 29, that is, after 28 days of treatment with theramine and tenoxicam and their combination, using the Medical Outcomes Study Short-Form 36 assessment questionnaire. Significant negative changes in indicators of both physical and mental components of health were revealed. It was established that in terms of impact on the quality of life in patients with low back pain, monotherapy with theramine and tenoxicam is inferior to their combined use. The highest physical activity level has been found to follow taking combined medication and the lowest one – after tenoxicam intake, the similar changes having been found with the indicator of physical role functioning. Pain intensity was best affected by combined therapy, the effect of theramin and tenoxicam being similar. It is also shown that theramine prevailed over tenoxicam in terms of its effect on indicators of physical and mental components of health. The results of the research on theramine and its combined use with tenoxicam should be included in the treatment programme for patients with low back pain in order to improve the quality of life
Received: 28.07.2023 | Revised: 24.10.2023 | Accepted: 28.11.2023
References
George SZ, Fritz JM, Silfies SP, Schneider MJ, Beneciuk JM, Lentz TA, et al. Interventions for the management of acute and chronic low back pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):1–60. DOI: 10.2519/jospt.2021.0304
North American Spine Society. Evidence-based clinical guidelines for multidisciplinary spine care: Diagnosis and treatment of low back pain [document on the Internet]. NASS; 2020. [cited 2024 Jan 23]. Available from: https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf
Casiano VE, Sarwan G, Dydyk AM, Varacallo M. Back pain. In: StatPearls [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/30844200/
Pangarkar SS, Kang DG, Sandbrink F, Bevevino A, Tillisch K, Konitzer L, Sall J. VA/DoD clinical practice guideline: Diagnosis and treatment of low back pain. J Gen Intern Med. 2019;34(11):2620–29. DOI: 10.1007/s11606-019-05086-4
Kopchak O. Lower back pain: Evidence-based insights. Int Neurol J. 2020;16(3):41–49. DOI: 10.22141/2224-0713.16.3.2020.202769
Povoroznyuk V, Musiienko A, Zaverukha N, Tkachuk A. Efficacy and safety of Ketoprofen Gel treatment in patients with low back pain. Pain, Joints, Spine. 2021;11(1):28–34. DOI: 10.22141/2224-1507.11.1.2021.226906
Smiian S. Congruence of inflammatory back pain and anti-inflammatory treatment. Health Ukr. Cardiol. Reum. Cardiac Surg. 2020; 4(71):23.
Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians, Denberg TD, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American college of physicians. Ann Intern Med. 2017;166(7):514–30. DOI: 10.7326/M16-2367
Jiang J, Pan H, Chen H, Song L, Wang Y, Qian B, et al. Comparative efficacy of pharmacological therapies for low back pain: A Bayesian network analysis. Front Pharmacol. 2022;13:e811962. DOI: 10.3389/fphar.2022.811962
Shell WE, Pavlik S, Roth B, Silver M, Breitstein ML, May L, Silver D. Reduction in pain and inflammation associated with chronic low back pain with the use of the medical food theramine. Am J Ther. 2016;23(6):1353–62. DOI: 10.1097/MJT.0000000000000068
Romanenko V. Lower back pain: Contemporary perspectives on treatment. Health Ukr. Neurol. Psychiatry. Psychother. 2020;4(55):31.
Zhdan V, Ivanitskii IV, Katerenchuk OI, Shilkina LM. Optimization of therapy in patients with lower back pain depending on the presence of benign joint hypermobility syndrome. Ukr J Med Biol Sports. 2021;29(1):78–83. DOI: 10.26693/jmbs06.01.078
Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):383–12. DOI: 10.1002/acr.20541
The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. Available from: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/
Andorno R. Global bioethics at UNESCO: In defence of the Universal declaration on bioethics and human rights. J Med Ethics. 2007;33(3):150–54. DOI: 10.1136/jme.2006.016543
Ministry of Health of Ukraine. On the approval of the procedure for conducting clinical trials of medicinal products and expertise of materials of clinical trials, and the standard regulation on ethics committees [Internet]. 2009 [cited 2024 Jan 23]. Order No. 1010/17026. 2009 October 29. Available from: https://zakon.rada.gov.ua/laws/show/z1010-09
Cheng H, Mollica MY, Lee SH, Wang L, Velázquez-Martínez CA, Wu S. Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-NSAIDs) on melanoma cell adhesion. Toxicol Appl Pharmacol. 2012;264(2):161–66. DOI: 10.1016/j.taap.2012.07.029
Shell WE, Charuvastra EH, DeWood MA, May LA, Bullias DH, Silver DS. A double-blind controlled trial of a single dose naproxen and an amino acid medical food theramine for the treatment of low back pain. Am J Ther. 2012;19(2):108–14. DOI: 10.1097/MJT.0b013e3181f4b297
Bhatia A, Engle A, Cohen SP. Current and future pharmacological agents for the treatment of back pain. Expert Opin Pharmacother. 2020;21(8):857–61. DOI: 10.1080/14656566.2020.1735353
Tenoxicam: Features of use in clinical practice. Ukr J Rheumatol. 2020;1(79):60–64. DOI: 10.32471/rheumatology.2707-6970.79.14869
Coull JT, Hwang HJ, Leyton M, Dagher A. Dopamine precursor depletion impairs timing in healthy volunteers by attenuating activity in putamen and supplementary motor area. J Neurosci. 2012;32(47):16704–15. DOI: 10.1523/JNEUROSCI.1258-12.2012
Mette C, Zimmermann M, Grabemann M, Abdel-Hamid M, Uekermann J, Biskup CS, et al. The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD. Acta Psychiatr Scand. 2013;128(2):124–32. DOI: 10.1111/acps.12090
Ablin JN, Buskila D, Van Houdenhove B, Luyten P, Atzeni F, Sarzi-Puttini P. Is fibromyalgia a discrete entity?. Autoimmun Rev. 2012;11(8):585–88. DOI: 10.1016/j.autrev.2011.10.018
Vogel J, Wilke J, Krause F, Vogt L, Niederer D, Banzer W. Functional movement analysis in patients with chronic nonspecific low back pain: A reliability and validity study. BMC Musculoskelet Disord. 2019;20:e395. DOI: 10.1186/s12891-019-2779-6
McMahon SB, Dargan P, Lanas A, Wiffen P. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty. Curr Med Res Opin. 2021;37(2):287–92. DOI: 10.1080/03007995.2020.1847718
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Volodymyr Shmanko, Iryna Dzikh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
